181 related articles for article (PubMed ID: 16226682)
1. Atheroprotective effects of high-density lipoprotein-associated lysosphingolipids.
Nofer JR; Assmann G
Trends Cardiovasc Med; 2005 Oct; 15(7):265-71. PubMed ID: 16226682
[TBL] [Abstract][Full Text] [Related]
2. Atheroprotective role of high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P).
Potì F; Simoni M; Nofer JR
Cardiovasc Res; 2014 Aug; 103(3):395-404. PubMed ID: 24891400
[TBL] [Abstract][Full Text] [Related]
3. High-density lipoprotein metabolism and endothelial function.
Lowenstein CJ; Cameron SJ
Curr Opin Endocrinol Diabetes Obes; 2010 Apr; 17(2):166-70. PubMed ID: 20125006
[TBL] [Abstract][Full Text] [Related]
4. Anti-atherogenic effects of high-density lipoprotein on nitric oxide synthesis in the endothelium.
Andrews KL; Moore XL; Chin-Dusting JP
Clin Exp Pharmacol Physiol; 2010 Jul; 37(7):736-42. PubMed ID: 20374256
[TBL] [Abstract][Full Text] [Related]
5. High density lipoprotein-associated lysosphingolipids reduce E-selectin expression in human endothelial cells.
Nofer JR; Geigenmüller S; Göpfert C; Assmann G; Buddecke E; Schmidt A
Biochem Biophys Res Commun; 2003 Oct; 310(1):98-103. PubMed ID: 14511654
[TBL] [Abstract][Full Text] [Related]
6. Current understanding of the role of high-density lipoproteins in atherosclerosis and senescence.
Nofer JR; Walter M; Assmann G
Expert Rev Cardiovasc Ther; 2005 Nov; 3(6):1071-86. PubMed ID: 16292998
[TBL] [Abstract][Full Text] [Related]
7. Sphingosine-1-phosphate: A bioactive lipid that confers high-density lipoprotein with vasculoprotection mediated by nitric oxide and prostacyclin.
Rodríguez C; González-Díez M; Badimon L; Martínez-González J
Thromb Haemost; 2009 Apr; 101(4):665-73. PubMed ID: 19350109
[TBL] [Abstract][Full Text] [Related]
8. High-density lipoproteins, inflammation and oxidative stress.
Tabet F; Rye KA
Clin Sci (Lond); 2009 Jan; 116(2):87-98. PubMed ID: 19076062
[TBL] [Abstract][Full Text] [Related]
9. [Measurement of sphingosine 1-phosphate as a biomarker of atherosclerosis].
Kimura T; Okajima F; Murakami M
Rinsho Byori; 2007 Apr; 55(4):358-62. PubMed ID: 17511266
[TBL] [Abstract][Full Text] [Related]
10. High-density lipoproteins, platelets and the pathogenesis of atherosclerosis.
Nofer JR; Brodde MF; Kehrel BE
Clin Exp Pharmacol Physiol; 2010 Jul; 37(7):726-35. PubMed ID: 20337657
[TBL] [Abstract][Full Text] [Related]
11. Multiple actions of high-density lipoprotein.
Florentin M; Liberopoulos EN; Wierzbicki AS; Mikhailidis DP
Curr Opin Cardiol; 2008 Jul; 23(4):370-8. PubMed ID: 18520722
[TBL] [Abstract][Full Text] [Related]
12. Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids.
Nofer JR; Levkau B; Wolinska I; Junker R; Fobker M; von Eckardstein A; Seedorf U; Assmann G
J Biol Chem; 2001 Sep; 276(37):34480-5. PubMed ID: 11432865
[TBL] [Abstract][Full Text] [Related]
13. HDL-like lipoproteins in cerebrospinal fluid affect neural cell activity through lipoprotein-associated sphingosine 1-phosphate.
Sato K; Malchinkhuu E; Horiuchi Y; Mogi C; Tomura H; Tosaka M; Yoshimoto Y; Kuwabara A; Okajima F
Biochem Biophys Res Commun; 2007 Aug; 359(3):649-54. PubMed ID: 17544365
[TBL] [Abstract][Full Text] [Related]
14. Selective attenuation of Toll-like receptor 2 signalling may explain the atheroprotective effect of sphingosine 1-phosphate.
Dueñas AI; Aceves M; Fernández-Pisonero I; Gómez C; Orduña A; Crespo MS; García-Rodríguez C
Cardiovasc Res; 2008 Aug; 79(3):537-44. PubMed ID: 18411230
[TBL] [Abstract][Full Text] [Related]
15. The antiatherogenic and antiinflammatory effect of HDL-associated lysosphingolipids operates via Akt -->NF-kappaB signalling pathways in human vascular endothelial cells.
Schmidt A; Geigenmüller S; Völker W; Buddecke E
Basic Res Cardiol; 2006 Mar; 101(2):109-16. PubMed ID: 16450077
[TBL] [Abstract][Full Text] [Related]
16. Myeloperoxidase-mediated oxidation of high-density lipoproteins: fingerprints of newly recognized potential proatherogenic lipoproteins.
Malle E; Marsche G; Panzenboeck U; Sattler W
Arch Biochem Biophys; 2006 Jan; 445(2):245-55. PubMed ID: 16171772
[TBL] [Abstract][Full Text] [Related]
17. Long pentraxin 3, a key component of innate immunity, is modulated by high-density lipoproteins in endothelial cells.
Norata GD; Marchesi P; Pirillo A; Uboldi P; Chiesa G; Maina V; Garlanda C; Mantovani A; Catapano AL
Arterioscler Thromb Vasc Biol; 2008 May; 28(5):925-31. PubMed ID: 18218986
[TBL] [Abstract][Full Text] [Related]
18. High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor.
Theilmeier G; Schmidt C; Herrmann J; Keul P; Schäfers M; Herrgott I; Mersmann J; Larmann J; Hermann S; Stypmann J; Schober O; Hildebrand R; Schulz R; Heusch G; Haude M; von Wnuck Lipinski K; Herzog C; Schmitz M; Erbel R; Chun J; Levkau B
Circulation; 2006 Sep; 114(13):1403-9. PubMed ID: 16982942
[TBL] [Abstract][Full Text] [Related]
19. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice.
Nofer JR; Bot M; Brodde M; Taylor PJ; Salm P; Brinkmann V; van Berkel T; Assmann G; Biessen EA
Circulation; 2007 Jan; 115(4):501-8. PubMed ID: 17242282
[TBL] [Abstract][Full Text] [Related]
20. The paradox of dysfunctional high-density lipoprotein.
Ansell BJ; Fonarow GC; Fogelman AM
Curr Opin Lipidol; 2007 Aug; 18(4):427-34. PubMed ID: 17620860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
